J&J Settlement Inspires PA Legislators on False Claims Act


Following Johnson & Johnson’s $2.2 billion settlement for off-label marketing and kickbacks related to its antipsychotic Risperdal, Pennsylvania legislators Brandon Neuman and Tony DeLuca are renewing their push for a Pennsylvania version of the False Claims Act.  Whistleblowers in three states will collect $167.7 million under the federal False Claims Act, they say, while Pennsylvania remains the largest state in the union without such a law. “Pennsylvanians lose as much as $200 million a year through Medicare and Medicaid fraud and abuse,” according to Neuman, “Our Pennsylvania False Claims Act legislation … would go a long way toward deterring this dishonesty.”

Article →

Of further interest:
Johnson & Johnson, Janssen settle off-label Risperdal claims for $2.2 billion (Pennsylvania Record)

Previous article“Dr. Lieberman and ’60 Minutes’”
Next articleDrugNews
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].


  1. First 2 things I thought of after reading this:


    One in six adolescents were taking antipsychotic medications by the end of a five-year study of 686,000 children in foster care in 48 states. Other psychoactive medication and the use of multiple simultaneous medications (“polypharmacy”) were declining by the end of the study. “We’re not saying these medications should never be used for children, but the high rate at which they’re used by children in foster care indicates that other interventions and supports, such as trauma-based counseling, may not be in place for them,” said one author.



    NAMI – Pharmaceutical Front Group


    Report comment